Laboratorios Farmacéuticos ROVI - Investing for future growth
Laboratorios Farmacéuticos ROVI has reported a strong set of FY19 results, with all pillars of the business contributing to revenue growth of 26%...
627 Views
Laboratorios Farmacéuticos ROVI - Multiple growth drivers lie ahead
Following Laboratorios Farmacéuticos ROVI’s (ROVI’s) recent investor day, we have reviewed our near-term forecasts. Specifically, we upgrade our...
1.5k Views
Laboratorios Farmacéuticos ROVI - Robust growth across key franchises
Laboratorios Farmacéuticos ROVI (ROVI) has reported operating revenue of €270.8m (+24% y-o-y) for the first nine months of FY19 (9M19), driven by...
855 Views
Laboratorios Farmacéuticos ROVI - DORIA on target for US NDA in H219
ROVI has announced its pivotal Phase III PRISMA-3 trial continues on track and it expects to file an NDA with the FDA in the second half of 2019....
64 Views
Laboratorios Farmacéuticos ROVI - DORIA low risk, high reward
Laboratorios Farmacéuticos ROVI’s (ROVI) investment case rests on the growth opportunities in its speciality pharmaceuticals portfolio, in...
47 Views